MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
April 12 2023 - 4:05PM
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell therapeutics and to
support innovative cell-based research, today announced that it
will release financial results for the first quarter 2023 after the
U.S. market close on Wednesday, May 10th, 2023. Company management
will host a conference call to discuss financial results at 4:30
p.m. Eastern Time.
Earnings Conference Call
DetailsInvestors interested in listening to the conference
call are required to register online. It is recommended to register
at least a day in advance. A live and archived webcast of the event
will be available on the “Events” section of the MaxCyte website at
https://investors.maxcyte.com/.
About MaxCyteAt MaxCyte, we pursue
cell engineering excellence to maximize the potential of cells to
improve patients’ lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today’s
processes to innovate tomorrow’s solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been
designed to support the rapidly expanding cell therapy market and
can be utilized across the continuum of the high-growth cell
therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx ™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn.
MaxCyte Contacts:
US IR AdviserGilmartin
GroupDavid Deuchler, CFA+1 415-937-5400ir@maxcyte.com
Nominated Adviser and Joint Corporate
BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500
UK IR AdviserConsilium
Strategic CommunicationsMary-Jane Elliott / Chris Welsh+44
(0)203 709 5700maxcyte@consilium-comms.com
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024